TEDCO invests $500K in Nodal Therapeutics' lymph-node immunotherapy platform
What's the deal? TEDCODealroom has a profile for this one. Try Dealroom →, Maryland's economic development corporation for technology companies, has invested $500,000 in Nodal Therapeutics, a Silver Spring-based startup developing a novel immunotherapy platform to treat autoimmune diseases. The investment came through TEDCO's Life Science Investment Fund, part of its Seed Funds programme supporting early-stage tech and life sciences companies across the state.
Nodal Therapeutics is building technology that introduces degradable depots directly into lymph nodes, turning them into "tolerance factories" that rebalance the body's immune response. The tech was invented in the lab of Prof. Christopher Jewell at the University of Maryland, College Park.
"Our precision control solution is potent, selective and will allow for a long-lasting tolerance that cures autoimmune diseases without the side-effects of existing therapies," said Klaus Martin, chief executive officer of Nodal Therapeutics.
Why now? Maryland has been positioning itself as a leading biopharma cluster, with recent milestones including a $2B investment from AstraZenecaDealroom has a profile for this one. Try Dealroom →. Nodal Therapeutics first connected with TEDCO through the Maryland Innovation Initiative, a programme linking the state's five academic research institutions with commercial opportunities.
"These achievements would not be possible without the state's continued investment in innovation and growth," said TEDCO chief executive officer Troy LeMaile-Stovall.
What could go wrong? Autoimmune therapies face long, expensive development timelines and high regulatory hurdles. A $500,000 seed investment is modest for the life sciences sector, where clinical trials alone can cost tens of millions. Nodal will likely need significant follow-on funding to advance its platform beyond early research.
The signal: TEDCO's classification as an investment fund underscores Maryland's institutional approach to seeding life sciences startups with public capital. The $500,000 cheque is small by biotech standards, but state-backed vehicles like TEDCO's Life Science Investment Fund serve a specific purpose — de-risking university spin-outs at a stage where private venture capital rarely engages, potentially setting the table for larger follow-on rounds as Nodal's lymph-node platform matures toward preclinical milestones.
Read more: citybiz.co
